Cure8 news brief
Positive Phase 3 pediatric data could expand access to Omvoh for children with ulcerative colitis and change treatment options. That matters to families, clinicians, and patients using or considering biologic therapy.
Pediatric patients with ulcerative colitis and their caregivers; clinicians treating pediatric IBD; patients on or considering Omvoh; IBD researchers.
A Lilly-funded Phase 3 trial (SHINE-2) tested Omvoh in children aged 4–17 with moderately to severely active ulcerative colitis. Among the subgroup aged 6–17 who initially responded, about half were in clinical remission at Week 52, and safety in the study was described as consistent with the adult profile.
Lilly says four serious adverse events occurred but were judged unrelated to treatment; two patients discontinued for worsening disease. Next steps for patients and clinicians include watching for Lilly’s regulatory submissions and any decisions by regulators about pediatric labeling.
The company’s announcement frames this as a label-expansion opportunity rather than a new drug approval.
This is a company report in financial news summarizing Phase 3 results and planned regulatory steps. Full peer-reviewed data and regulator review will determine whether a pediatric label is granted.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This press release reports multi-year data suggesting many patients treated continuously with mirikizumab maintained clinical remission and endoscopic response at two years—outcomes people with Crohn’s disease often care...
This article reports two-year data showing that mirikizumab (Omvoh) maintained clinical and endoscopic benefit for many people with moderate–severe Crohn’s disease, and that results across Phase 3 programs also support...
This press release reports multi-year clinical trial data suggesting sustained remission and intestinal healing with Omvoh (mirikizumab) in patients with Crohn's disease—information that could affect treatment...
